SYBXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:59):

Stats
本日の出来高	4 131.00
平均出来高	137 679
時価総額	21.89M
EPS	$0 ( 2024-04-03 )
次の収益日	( $-0.800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0.0100 (0.53%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Dooley Mary Beth	Sell	188	Common Stock
2024-04-02	Awad Antoine	Sell	372	Common Stock
2024-03-18	Dooley Mary Beth	Sell	0	Common Stock
2024-03-18	Dooley Mary Beth	Sell	3 612	Stock Option (right to buy)
2024-03-19	Flynn James P	Buy	4 000	Stock Option (right to buy)

INSIDER POWER
-63.26
Last 97 transactions
Buy: 6 126 214 \| Sell: 2 856 834

Synlogic Inc 相関

10 最も正の相関
APOP	0.931
RMRM	0.927
TLGT	0.86
AUR	0.859
PAIC	0.836
SVOK	0.83
FEYE	0.827
TDAC	0.824
SVAC	0.824
CMLF	0.824

10 最も負の相関
MMAC	-0.916
AMRB	-0.869
BOCH	-0.865
NETE	-0.85

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Synlogic Inc 財務諸表

Annual	2023
収益:	$3.37M
総利益:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2023
収益:	$3.37M
総利益:	$-1.92M (-57.08 %)
EPS:	$-8.81

FY	2022
収益:	$1.18M
総利益:	$-4.49M (-380.42 %)
EPS:	$-13.57

FY	2021
収益:	$1.75M
総利益:	$0.00 (0.00 %)
EPS:	$-1.090

Financial Reports:

No articles found.

Synlogic Inc

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.